5.04

6.33% 0.30

Cns Pharmaceuticals Inc (CNSP)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.74

Aprire:

$4.825

Volume 24 ore:

7,539

Relative Volume:

0.01

Capitalizzazione di mercato:

$7.37M

Reddito:

Utile/perdita netta:

$-16.49M

Rapporto P/E:

-0.1701

EPS:

-29.6295

Flusso di cassa netto:

$-15.24M

1 W Prestazione:

-2.42%

1M Prestazione:

+11.26%

6M Prestazione:

-28.41%

1 anno Prestazione:

-53.12%

Intervallo 1D:

$4.66

$5.05

Intervallo di 1 settimana:

$4.61

$5.27

Portata 52W:

$1.90

$10.59

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Nome

Cns Pharmaceuticals Inc

Settore

Healthcare (1092)

Industria

Biotechnology (603)

Telefono

1-800-946-9185

Indirizzo

2100 WEST LOOP SOUTH, HOUSTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

CNSP's Discussions on Twitter

Compare CNSP vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CNSP Cns Pharmaceuticals Inc	5.04	6.93M	0	-16.49M	-15.24M	-29.63
VRTX Vertex Pharmaceuticals Inc	485.65	123.36B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.69	71.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	860.55	53.68B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	186.16	38.09B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	267.47	37.80B	4.29B	577.22M	641.34M	4.2086

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-12-28	Downgrade	Ladenburg Thalmann	Buy → Neutral
2020-08-24	Iniziato	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

Jul 06, 2026

CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo

Jul 06, 2026

Jul 05, 2026

CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber

Jul 05, 2026

Jul 03, 2026

CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et

Jul 03, 2026

Jul 02, 2026

CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks

Jul 02, 2026

CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView

Jul 02, 2026

Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan

Jul 02, 2026

Jul 01, 2026

CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView

Jul 01, 2026

Jun 28, 2026

CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Stage Pressures - dars.gov.et

Jun 28, 2026

Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView

Jun 28, 2026

CNS Pharmaceuticals (CNSP) Dips 4% as Shares Approach Key Support LevelTPO Profile - dars.gov.et

Jun 28, 2026

Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView

Jun 28, 2026

Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView

Jun 25, 2026

CNSP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in FocusSwing Entry Signals - dars.gov.et

Jun 25, 2026

Jun 23, 2026

SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News

Jun 23, 2026

Jun 22, 2026

ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire

Jun 22, 2026

Jun 20, 2026

Why did CNSP stock surge 330% today? - MSN

Jun 20, 2026

Jun 18, 2026